Paul Howard is a senior fellow at the Manhattan Institute and director of health policy. He is a contributor to The Apothecary, the Forbes blog on health-care policy and entitlement reform, and a regular columnist for The Morning Consult. Along with Peter Huber, he is the co-author of Unlocking Precision Medicine (Encounter Books, 2016).

Howard has written on a wide variety of medical-policy issues, including FDA reform, biopharmaceutical innovation, consumer-driven health care, and Medicare and Medicaid reform. He is often quoted on health-care issues, and his work has appeared in such publications as Bloomberg View, New York Times, Wall Street Journal, National Affairs, USA Today, RealClearPolitics, New York Post, Investor’s Business Daily, Health Affairs, and He is a member of MI’s Project FDA.

Howard was part of the health-care policy advisory group for Mitt Romney’s 2012 presidential campaign, has testified three times before Congress, and, during 2013–16, served on an expert panel as a judge for Celgene’s Innovation Impact Awards. He joined MI in 2000, as deputy director of its Center for Legal Policy, where he edited research papers, managed legal-policy analyses, and organized conferences. He holds a B.A. from the College of the Holy Cross and a Ph.D. in political science from Fordham University.

Recent Posts by Paul Howard

The Burgeoning “Yelpification” Of Health Care: Foundations Help Consumers Hold A Scale And A Mirror To The Health Care System

Current information about health care quality is disconnected from what consumers want. Philanthropy has a role to play in bridging the disconnect.

May 25, 2017GrantWatch, Hospitals, Quality

If A Drug Is Good Enough For Europeans, It’s Good Enough For Us

Note: This post is coauthored by Paul Howard and Yevgeniy Feyman of the Manhattan Institute. Meningitis is a terrible disease that can kill its victims in a single day. About 4,100 new cases are diagnosed annually in the U.S., with a mortality rate of more than 10 percent. Even with...

The Real Problem With Withdrawing Avastin

In late December, the Food and Drug Administration (FDA) revoked approval of the cancer drug Avastin for metastatic breast cancer. The decision set off a firestorm of reaction: the right condemned the denial of a potential life-saving drug for breast cancer patients, while the left cheered the...

January 19, 2011Drugs and Medical Technology